Three things to know:
1. The Ottawa, Canada-based company is in the pre-clinical stage of developing a biomaterial that uses plant-derived cellulose to generate “scaffold architectures” for regenerative medicine.
2. Spiderwort’s biomaterials demonstrated promise for the treatment of spinal cord injuries and soft tissue regeneration in pre-clinical trials.
3. The company, which recently moved into a biotechnology research facility in Ottawa, plans to use the funding to reach clinical trials.
More articles on biologics:
How Dr. Vladimir Sinkov opened his solo spine practice in the midst of the COVID-19 pandemic
Steadman Clinic moves to absorb hospital orthopedic group — 6 things to know
Michigan group to open 7th location, add 2 orthopedic surgeons
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
